A causal role for remnant cholesterol in cardiovascular disease revealed.

REPROGRAM researchers of the Academic Medical Center (AMC) teamed up with researchers from Copenhagen, Denmark (REGIONH) to study the impact of remnant cholesterol on arterial wall inflammation, circulating monocytes, and bone marrow in patients with familial dysbetalipoproteinemia (FD).

Although the population with FD is an extreme model, elevated levels of (nonfasting) remnant cholesterol are present in 38% of men and 20% of women in the general population, 23 emphasizing the importance of better understanding its relationship with cardiovascular disease. This study provides important novel pathophysiological insights in the atherogenicity of remnant cholesterol, showing increased arterial inflammation and bone marrow activation in patients wit elevated levels of remnant cholesterol. These findings indicate an important multilevel inflammatory component to the atherogenicity of remnant cholesterol, which may contribute to its relation with increased CV risk.

Full results of this collaborative action are published in Arteriosclerosis, Thrombosis, and Vascular Biology and can be found here or DOI: 10.1161/ATVBAHA.116.308834


This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°667837.